Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Transfer RNA (tRNA) is the essential, often overlooked, molecule that provides the critical translation of genetic code into the proteins that are the building blocks of life. We are creating engineered tRNAs with the power to overcome disease-causing issues in the genetic code as proteins are made.
“If you are working on something exciting that you really care about, you don’t have to be pushed. The vision pulls you.”
Christine Foster is a seasoned business leader with more than 30 years of experience in large pharmaceutical and biotechnology companies.
Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a Founder and Director of Corixa Corporation and served as the company’s Chief Executive Officer.
David focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics.
Sacha Mann is a Senior Partner at Takeda Ventures. She has a decade of experience in venture investing and complimentary skills in company creation, management as biotech CEO, business development, and R&D.
Brad Margus currently serves as Executive Chair of Cerevance, a clinical-stage drug development company that he co-founded and led as Chief Executive Officer from 2016 to April 2022, focused on pursuing novel targets for brain diseases.
Benjamin has been a partner at Panacea Venture since 2018, he is a scientist, entrepreneur, investor and merchant banker.
Dr. Miyahara is a Senior Investment Director at Taiho Ventures with over 18 years of experience in the life sciences industry.
Leslie J Williams, a 25-year biopharmaceutical industry veteran, is an experienced biotech CEO and board of directors’ member with demonstrated expertise in building companies, raising funds, and negotiating strategic collaborations.
PhD
Craig is Chairman of the Science Advisory Board and the Blais University Chair in Molecular Medicine at the University of Massachusetts Medical School (UMMS).
MD, PhD
Dr. John F. DiPersio is Chief of the Division of Oncology, Deputy Director of the Siteman Cancer Center at Washington University School of Medicine in St. Louis, and the Virginia E. and Samuel J. Golman Professor of Medicine.
DVM
Biotechnology Consultant
Page Bouchard is an independent biotechnology consultant with a focus on preclinical R&D and regulatory drug development.
MD, PhD
Dr. Oladapo Yeku is an Assistant Professor of Medicine at Harvard Medical School and a Clinical Assistant in Medicine at the Massachusetts General Hospital.
PhD
EVP, Head of Oncology Practice
Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting, formerly Defined Health.
PhD
John Lueck is Assistant Professor in Department of Pharmacology and Physiology and is a member of The Center for RNA Biology the University of Rochester Medical Center
PhD
Christopher Ahern is a Professor in the Department of Molecular Physiology and Biophysics and the Iowa Neuroscience Institute.
PhD
Dr. Maier joined Alnylam Pharmaceuticals in 2006 where he currently serves as Senior Vice President, heading the Oncology group.
PhD
Tao Pan is a Professor of Biochemistry and Molecular Biology at the University of Chicago. Throughout his career he has made many contributions to RNA biology, RNA biochemistry, and RNA technology.
If you are interested in partnering with us, reach out here at info@hcbioscience.com
hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Christine Foster, DPhil, as Chief Business Officer to lead the Company’s global business development and strategic partnering activities. She brings extensive experience in identifying, structuring, and executing partnerships and M&A transactions, including within the field of gene editing.
hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics. Their technologies will be used to discover and optimize tRNAs capable of overcoming genetic errors to treat genetic disease and cancer.
hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced an extension of $16 million to its Series A funding round, bringing the total raised to $40 million. Taiho Ventures and Panacea Venture joined existing investors, ARCH Venture Partners, Takeda Ventures and 8VC.
A Takeda and ARCH-backed startup looking to prove out the next potential RNA goldmine in drug R&D has secured more capital en route to a 2024 clinical entry, CEO Leslie Williams tells Endpoints News.
hC Bioscience, Inc., a company developing first-
in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors.
“We are excited to welcome Brad to the company during this pivotal time of growth,”
said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience.
Nonsense mutations change an amino acid codon to a premature termination codon (PTC) generally through a single-nucleotide substitution…
The appearance of the premature translation termination codons (PTCs)…